Your browser doesn't support javascript.
loading
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.
Jiang, Bei-Er; Jiang, Xingwu; Zhang, Qiansen; Liang, Qiuwen; Qiu, Zi-Liang; Sun, Xiang-Bai; Yang, Jun-Jie; Chen, Si; Yi, Chunyang; Chai, Xiaolei; Liu, Mingyao; Yu, Li-Fang; Lu, Weiqiang; Zhang, Han-Kun.
Afiliação
  • Jiang BE; Drug Discovery Unit, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai 200241, P. R. China.
  • Jiang X; Navy Medical Research Institute, Second Military Medical University, Shanghai 200433, P. R. China.
  • Zhang Q; Drug Discovery Unit, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai 200241, P. R. China.
  • Liang Q; Department of Materials Science, Fudan University, Shanghai 200433, P. R. China.
  • Qiu ZL; Drug Discovery Unit, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai 200241, P. R. China.
  • Sun XB; Drug Discovery Unit, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai 200241, P. R. China.
  • Yang JJ; Drug Discovery Unit, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai 200241, P. R. China.
  • Chen S; Drug Discovery Unit, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai 200241, P. R. China.
  • Yi C; Drug Discovery Unit, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai 200241, P. R. China.
  • Chai X; Drug Discovery Unit, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai 200241, P. R. China.
  • Liu M; Drug Discovery Unit, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai 200241, P. R. China.
  • Yu LF; Drug Discovery Unit, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai 200241, P. R. China.
  • Lu W; Drug Discovery Unit, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai 200241, P. R. China.
  • Zhang HK; Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, P. R. China.
J Med Chem ; 64(1): 385-403, 2021 01 14.
Article em En | MEDLINE | ID: mdl-33382613
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Escleroderma Sistêmico / Drogas Desenhadas / Receptor CB2 de Canabinoide / Descoberta de Drogas Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Escleroderma Sistêmico / Drogas Desenhadas / Receptor CB2 de Canabinoide / Descoberta de Drogas Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article